AD GWAS in African Americans Confirms, Reshuffles AlzGene List
News Apr 11, 2013
This gene, for a membrane transporter protein called ABCA7, is the greatest difference between African American and Caucasian Alzheimer’s risk to emerge from the largest genomewide association study (GWAS) for AD performed in African Americans to date. The study appears April 10 in the Journal of the American Medical Association. In African Americans, ABCA7 variation is the strongest genetic risk factor for AD outside of the ApoE4 allele. Other than that, the genes involved in African American AD risk paralleled those in whites, reported the study authors representing the Alzheimer's Disease Genetics Consortium.
Led by senior author Richard Mayeux at Columbia University in New York City, the researchers examined single-nucleotide polymorphisms from nearly 2,000 people with late-onset Alzheimer’s, and almost 4,000 control participants. The group collected all the data it could get from African Americans seen at more than 20 study centers, said first author Christiane Reitz, also at Columbia.
While many of the previously reported GWAS data come from people of European and European American ancestry, Reitz noted that it is important to investigate whether those genetic findings extend to people beyond that white slice of humanity. A GWAS in Hispanics is ongoing.
Several of the genes the current study picked out in African Americans matched those found in GWAS with white people. ApoE4 was the strongest risk factor; a single copy more than doubled risk of Alzheimer’s with an odds ratio of 2.31 in this report. “Replicating an association for the same alleles in different ethnic groups strengthens the case for these variants being important in increasing disease susceptibility,” commented Robert Nussbaum of the University of California, San Francisco, in an editorial accompanying the publication.
After ApoE, ABCA7 was second on the hit list. ABCA7 variants had been reported to increase risk in white people, but ABCA7 was in the middle of the pack among genes linked to AD, most of which boost risk by an average of 10-20 percent, Reitz said (Hollingworth et al., 2011). ABCA7 currently ranks fourth on the AlzGene Top 10. In the new study’s African American population, an ABCA7 variant increased one’s chances of AD by almost double, with an odds ratio of 1.79.
This kind of race-based difference is not uncommon, Reitz noted. She suspects that the ABCA7 polymorphisms found in Caucasians point to specific functional mutations different from those carried by African Americans, but the researchers have not yet sequenced the gene to check. It is also possible that the genetic background of each race, as well as environmental factors, conspire with ABCA7 variants to produce a higher risk in African American carriers than in whites.
It is too early to think about genetic testing or ABCA7-based therapies, Reitz said. For now, researchers have to confirm the disease association in an independent population and study the biological function of the gene. That is no small task. ABCA7’s functions fit with the AD literature in that lipid dysregulation and cardiovascular disease are known risk factors (Breteler, 2000; Shepardson et al., 2011). ABCA7 encodes an ATP-binding transporter that participates in lipoprotein biogenesis, and secretion of phospholipids and cholesterol (Tanaka et al., 2011). It also influences the transport of amyloid precursor protein across the plasma membrane (Chan et al., 2008). “There are multiple ways in which ABCA might affect risk of late-onset Alzheimer's disease,” the study authors wrote.
Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.